Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

cent body surface area (BSA), a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients received either REMICADE 5 mg/kg or placebo administered at weeks 0, 2 and 6, followed by maintenance treatment every 8 weeks. The REMICADE group continued on maintenance treatments every 8 weeks. Patients in the placebo group were crossed over at week 24 to receive REMICADE 5 mg/kg at weeks 24, 26 and 30, then every 8 weeks through week 46.

In EXPRESS, through week 24, adverse events (AEs) occurred at a higher incidence in the REMICADE group (82 percent) compared with the placebo group (71 percent). The only clinically significant laboratory abnormalities that occurred more frequently in the REMICADE group compared with the placebo group were elevated liver enzyme tests. There were more serious AEs (6 percent), including one fatal infection, in the REMICADE group than in the placebo group (3 percent). AEs observed were generally consistent with those described in the prescribing information, including information regarding serious infections. Please see "Important Safety Information" below.

About EXPRESS II

EXPRESS II was a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of REMICADE in 835 adult patients with chronic, stable plaque psoriasis involving at least 10 percent BSA, a minimum PASI score of 12 and who were candidates for phototherapy or systemic therapy. Patients were randomized to induction doses of REMICADE 3 mg/kg or 5 mg/kg or placebo at weeks 0, 2 and 6. Patients in the active induction treatment groups were randomized again at week 14 to receive either scheduled or "as-needed" maintenance treatment at the same dose administered during the induction phase. Patients in the placebo group were crossed over at week 16 to receive REMICADE 5 mg/kg at weeks 16, 18 and 22, then every 8 weeks through week 46.

In EXPRESS II, through week 14 (th
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
(Date:10/20/2014)... --  Mary,s Medicinals today announced that its 501(c)(3) ... of Operation Grow4Vets , a national, nonpartisan organization ... services to assist them in living with injuries sustained ... , An ever-increasing number of medical studies have ... for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain ...
(Date:10/19/2014)... DUBLIN , October 20, 2014 Shire ... James Bowling , Interim Chief Financial Officer (CFO), has notified the ... current role to pursue a new career opportunity as CFO of ... Q1 2015 and the company will commence a search for a ... commented: "James has helped build and lead a high-quality ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Conduct Conference Call on, December 10, 2007 to Discuss SNS-595 ... ... SOUTH SAN FRANCISCO, Calif., Nov. 29 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... announced that it,will present data on the company,s two lead product ...
... Raised Worldwide Awareness and Funds ... to Fight Aids, Tuberculosis and Malaria, SEATTLE, Nov. 28 ... and distributor, today announced,the successful conclusion of "Change Me," an ... their thoughts on how to make the,world a better place. ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 3Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 2Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 3
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... October 20, 2014 My Clients Plus ... software application. The new module enables easy administration ... full life-cycle quality care. , This application allows users ... their practice, attach a to-do item to a specific ... even set up reoccurring reminders for follow-ups. It's ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... by Milk Campaign Gives One Lucky Teen the Chance to be drawn ... ... Billionaire by day, Caped Crusader,by night; living a dual life is no ... him refuel and stay in top,shape after a night spent defeating Gotham ...
... CHARLESTON, S.C., May 28 ,The National Association ... The,HealthCentral Network, Inc. (http://www.HealthCentral.com ) announced ... join HealthCentral,s growing,community of patients, caregivers, advocates ... from incontinence. Muller will offer support,give incontinence ...
... 28 S&R Communications Group announced,Friday that they have created ... one lucky employee each day for the rest of the ... the S&R upper management in,response to months of rising gas ... have a tradition here that we are all proud of," ...
... blood lead levels raised risk of arrest in adulthood , , WEDNESDAY, ... at a young age are more likely to be arrested later ... PLoS Medicine is the first empirical evidence that elevated ... child, are associated with criminal behavior in young adulthood. , "I ...
... of Plant Biologists (ASPB) and the Sociedad Mexicana De Bioquimica ... June 2225, 2008 in the Fiesta Americana Hotel in Merida, ... annual meeting is the biology and agriculture of plant species ... focus on the international collaborations to study and improve these ...
... the decline in NeoStem,Inc.,s (Amex: NBS ) market ... NeoStem said, "We know of no business development at ... our share price.", Dr. Smith continued, "As announced ... in a total amount of $900,000, which includes a,strategic ...
Cached Medicine News:Health News:Batman Takes on Gotham City With a Little Help From Milk 2Health News:The National Association For Continence and The HealthCentral Network Form Alliance to Develop New Online Resources for Patients Coping with Incontinence 2Health News:The National Association For Continence and The HealthCentral Network Form Alliance to Develop New Online Resources for Patients Coping with Incontinence 3Health News:Lead Exposure in Childhood Linked to Criminal Behavior Later 2Health News:Lead Exposure in Childhood Linked to Criminal Behavior Later 3Health News:ASPB engages Latin America colleagues at Annual Meeting in Merida, Mexico June 22-25 2Health News:ASPB engages Latin America colleagues at Annual Meeting in Merida, Mexico June 22-25 3Health News:NeoStem, Inc. Comments on Recent Selling Pressure 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: